Terms: = Breast cancer AND FOXA1, TCF3A, 3169, ENSG00000129514, P55317, HNF3A, MGC33105 AND Treatment
89 results:
1. Clinically-observed foxa1 mutations upregulate SEMA3C through transcriptional derepression in prostate cancer.
Tam KJ; Liu L; Hsing M; Dalal K; Thaper D; McConeghy B; Yenki P; Bhasin S; Peacock JW; Wang Y; Cherkasov A; Rennie PS; Gleave ME; Ong CJ
Sci Rep; 2024 Mar; 14(1):7082. PubMed ID: 38528115
[TBL] [Abstract] [Full Text] [Related]
2. Identifying prognostic biomarkers for palbociclib add-on therapy in fulvestrant-resistant breast cancer using cell-free DNA sequencing.
Takeshita T; Iwamoto T; Niikura N; Watanabe K; Kikawa Y; Kobayashi K; Iwakuma N; Okamura T; Tada H; Ozaki S; Okuno T; Toh U; Yamamoto Y; Tsuneizumi M; Ishiguro H; Masuda N; Saji S
ESMO Open; 2024 Apr; 9(4):102385. PubMed ID: 38387111
[TBL] [Abstract] [Full Text] [Related]
3. PMM2 controls ERα levels and cell proliferation in ESR1 Y537S variant expressing breast cancer cells.
Cipolletti M; Acconcia F
Mol Cell Endocrinol; 2024 Apr; 584():112160. PubMed ID: 38266771
[TBL] [Abstract] [Full Text] [Related]
4. Methylation signatures as biomarkers for non-invasive early detection of breast cancer: A systematic review of the literature.
Gonzalez T; Nie Q; Chaudhary LN; Basel D; Reddi HV
Cancer Genet; 2024 Apr; 282-283():1-8. PubMed ID: 38134587
[TBL] [Abstract] [Full Text] [Related]
5. Architecture and topologies of gene regulatory networks associated with breast cancer, adjacent normal, and normal tissues.
Kumar S; Vindal V
Funct Integr Genomics; 2023 Oct; 23(4):324. PubMed ID: 37878223
[TBL] [Abstract] [Full Text] [Related]
6. Changes in cell-free DNA after short-term palbociclib and fulvestrant treatment for advanced or metastatic hormone receptor-positive and human epidermal growth factor 2-negative breast cancer.
Iwamoto T; Niikura N; Watanabe K; Takeshita T; Kikawa Y; Kobayashi K; Iwakuma N; Okamura T; Tada H; Ozaki S; Okuno T; Toh U; Yamamoto Y; Tsuneizumi M; Ishiguro H; Masuda N; Saji S
Breast Cancer Res Treat; 2024 Jan; 203(2):225-234. PubMed ID: 37875670
[TBL] [Abstract] [Full Text] [Related]
7. Tamoxifen-predictive value of gene expression signatures in premenopausal breast cancer: data from the randomized SBII:2 trial.
Lundgren C; Tutzauer J; Church SE; Stål O; Ekholm M; Forsare C; Nordenskjöld B; Fernö M; Bendahl PO; Rydén L
Breast Cancer Res; 2023 Sep; 25(1):110. PubMed ID: 37773134
[TBL] [Abstract] [Full Text] [Related]
8. Neoadjuvant Pyrotinib plus Trastuzumab, Docetaxel, and Carboplatin in Early or Locally Advanced Human Epidermal Receptor 2-Positive breast cancer in China: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.
Ding Y; Mo W; Xie X; Wang O; He X; Zhao S; Gu X; Liang C; Qin C; Ding K; Yang H; Ding X
Oncol Res Treat; 2023; 46(7-8):303-311. PubMed ID: 37302393
[TBL] [Abstract] [Full Text] [Related]
9. Endocrine resistance and breast cancer plasticity are controlled by CoREST.
Garcia-Martinez L; Adams AM; Chan HL; Nakata Y; Weich N; Stransky S; Zhang Z; Alshalalfa M; Sarria L; Mahal BA; Kesmodel SB; Celià-Terrassa T; Liu Z; Minucci S; Bilbao D; Sidoli S; Verdun RE; Morey L
Nat Struct Mol Biol; 2022 Nov; 29(11):1122-1135. PubMed ID: 36344844
[TBL] [Abstract] [Full Text] [Related]
10. Intercellular Communication Reveals Therapeutic Potential of Epithelial-Mesenchymal Transition in Triple-Negative breast cancer.
Liu Y; Fang Y; Bao L; Wu F; Wang S; Hao S
Biomolecules; 2022 Oct; 12(10):. PubMed ID: 36291687
[TBL] [Abstract] [Full Text] [Related]
11. A Unique foxa1-Associated Chromatin State Dictates Therapeutic Resistance in Lobular breast cancer.
Blawski R; Toska E
Cancer Res; 2022 Oct; 82(20):3668-3670. PubMed ID: 36245246
[TBL] [Abstract] [Full Text] [Related]
12. Integrated Bioinformatics Analysis for the Screening of Hub Genes and Therapeutic Drugs in Androgen Receptor-Positive TNBC.
Guo Q; Qiu P; Yao Q; Chen J; Lin J
Dis Markers; 2022; 2022():4964793. PubMed ID: 36157217
[TBL] [Abstract] [Full Text] [Related]
13. The antiviral drug telaprevir induces cell death by reducing foxa1 expression in estrogen receptor α (ERα)-positive breast cancer cells.
Bartoloni S; Leone S; Pescatori S; Cipolletti M; Acconcia F
Mol Oncol; 2022 Oct; 16(19):3568-3584. PubMed ID: 36056637
[TBL] [Abstract] [Full Text] [Related]
14. A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular breast cancer.
Nardone A; Qiu X; Spisak S; Nagy Z; Feiglin A; Feit A; Cohen Feit G; Xie Y; Font-Tello A; Guarducci C; Hermida-Prado F; Syamala S; Lim K; Munoz Gomez M; Pun M; Cornwell M; Liu W; Ors A; Mohammed H; Cejas P; Brock JB; Freedman ML; Winer EP; Fu X; Schiff R; Long HW; Metzger Filho O; Jeselsohn R
Cancer Res; 2022 Oct; 82(20):3673-3686. PubMed ID: 35950920
[TBL] [Abstract] [Full Text] [Related]
15. ARSD, a novel ERα downstream target gene, inhibits proliferation and migration of breast cancer cells via activating Hippo/YAP pathway.
Lin Y; Li C; Xiong W; Fan L; Pan H; Li Y
Cell Death Dis; 2021 Nov; 12(11):1042. PubMed ID: 34725332
[TBL] [Abstract] [Full Text] [Related]
16. The frequency of low HER2 expression in breast cancer and a comparison of prognosis between patients with HER2-low and HER2-negative breast cancer by HR status.
Horisawa N; Adachi Y; Takatsuka D; Nozawa K; Endo Y; Ozaki Y; Sugino K; Kataoka A; Kotani H; Yoshimura A; Hattori M; Sawaki M; Iwata H
Breast Cancer; 2022 Mar; 29(2):234-241. PubMed ID: 34622383
[TBL] [Abstract] [Full Text] [Related]
17. Prognosis Associated With Luminal and Basal Subtypes of Metastatic Prostate cancer.
Aggarwal R; Rydzewski NR; Zhang L; Foye A; Kim W; Helzer KT; Bakhtiar H; Chang SL; Perry MD; Gleave M; Reiter RE; Huang J; Evans CP; Alumkal JJ; Lang JM; Yu M; Quigley DA; Sjöström M; Small EJ; Feng FY; Zhao SG
JAMA Oncol; 2021 Nov; 7(11):1644-1652. PubMed ID: 34554200
[TBL] [Abstract] [Full Text] [Related]
18. Patient assessment and feasibility of treatment in older patients with cancer: results from the IN-GHO
Honecker F; Huschens S; Angermund R; Kallischnigg G; Freier W; Friedrich C; Hartung G; Lutz A; Otremba B; Pientka L; Späth-Schwalbe E; Kolb G; Bokemeyer C; Wedding U;
J Cancer Res Clin Oncol; 2021 Nov; 147(11):3183-3194. PubMed ID: 34312732
[TBL] [Abstract] [Full Text] [Related]
19. PARP-1 Regulates Estrogen-Dependent Gene Expression in Estrogen Receptor α-Positive breast cancer Cells.
Gadad SS; Camacho CV; Malladi V; Hutti CR; Nagari A; Kraus WL
Mol Cancer Res; 2021 Oct; 19(10):1688-1698. PubMed ID: 34158394
[TBL] [Abstract] [Full Text] [Related]
20. Nuclear FGFR1 Regulates Gene Transcription and Promotes Antiestrogen Resistance in ER
Servetto A; Kollipara R; Formisano L; Lin CC; Lee KM; Sudhan DR; Gonzalez-Ericsson PI; Chatterjee S; Guerrero-Zotano A; Mendiratta S; Akamatsu H; James N; Bianco R; Hanker AB; Kittler R; Arteaga CL
Clin Cancer Res; 2021 Aug; 27(15):4379-4396. PubMed ID: 34011560
[TBL] [Abstract] [Full Text] [Related]
[Next]
